Milestone Scientific (MLSS) 10-K 29 Mar 24 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 29, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0000855683
Entity Registrant Name	MILESTONE SCIENTIFIC INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-14053
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3545623
Entity Address, Address Line One	425 Eagle Rock Avenue
Entity Address, City or Town	Roseland
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07068
City Area Code	973
Local Phone Number	535-2717
Title of 12(b) Security	Common Stock, par value $.001 per share
Trading Symbol	MLSS
Security Exchange Name	NYSEAMER
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 40,047,188
Entity Common Stock, Shares Outstanding		76,602,116
Auditor Firm ID	688
Auditor Name	Marcum LLP
Auditor Location	East Hanover, New Jersey

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,977,713	$ 8,715,279
Marketable securities	2,976,573	0
Accounts receivable (net of allowance for credit losses of $10K at December 31, 2023 and 2022)	312,664	693,717
Prepaid expenses and other current assets	517,785	443,872
Inventories	2,638,186	1,792,335
Advances on contracts	1,371,548	1,325,301
Total current assets	10,794,469	12,970,504
Furniture, fixtures and equipment, net	10,024	18,146
Intangibles, net	178,636	227,956
Right of use assets finance lease	8,998	17,645
Right of use assets operating lease	355,235	443,685
Other assets	24,150	24,150
Total assets	11,371,512	13,702,086
Current liabilities:
Accrued expenses and other payables	1,511,717	1,124,839
Accrued expenses, related party	137,189	167,549
Accrued liabilities noncontrolling interests	214,000	0
Current portion of finance lease liabilities	10,264	9,365
Current portion of operating lease liabilities	103,427	91,701
Total current liabilities	3,076,713	3,299,675
Non-current portion of finance lease liabilities	434	10,698
Non-current portion of operating lease liabilities	281,853	385,279
Total liabilities	3,359,000	3,695,652
Commitments (see Note P)
Stockholders’ equity
Common stock, par value $.001; authorized 100,000,000 shares; 75,881,840 shares issued and 75,848,507 shares outstanding as of December 31, 2023 shares; 69,306,497 shares issued and 69,273,164 shares outstanding as of December 31, 2022;	75,881	69,306
Additional paid in capital	132,187,656	127,478,325
Accumulated deficit	(123,339,509)	(116,410,405)
Treasury stock, at cost, 33,333 shares	(911,516)	(911,516)
Total Milestone Scientific, Inc. stockholders' equity	8,012,512	10,225,710
Noncontrolling interest	0	(219,276)
Total stockholders’ equity	8,012,512	10,006,434
Total liabilities and stockholders’ equity	11,371,512	13,702,086
Nonrelated Party [Member]
Current liabilities:
Accounts payable	689,604	1,102,729
Related Party [Member]
Current liabilities:
Accounts payable	$ 410,512	$ 803,492

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Allowance for doubtful accounts	$ 10,000	$ 10,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	75,881,840	69,306,497
Common stock, shares outstanding (in shares)	75,848,507	69,273,164
Treasury stock, shares (in shares)	33,333	33,333

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Product sales, net	$ 9,827,444	$ 8,805,906
Cost of products sold	3,034,832	3,905,092
Gross profit	6,792,612	4,900,814
Selling, general and administrative expenses	13,135,796	12,514,323
Research and development expenses	701,378	1,150,209
Depreciation and amortization expense	61,912	63,755
Total operating expenses	13,899,086	13,728,287
Loss from operations	(7,106,474)	(8,827,473)
Interest income (expense)	125,527	54,607
Provision for income Taxes	0	0
Loss before provision for income taxes	(6,980,947)	(8,772,866)
Net loss	(6,980,947)	(8,772,866)
Net loss attributable to noncontrolling interests	(51,843)	(66,735)
Net loss attributable to Milestone Scientific Inc.	$ (6,929,104)	$ (8,706,131)
Net loss per share applicable to common stockholders—
Basic and Diluted (in dollars per share)	$ (0.1)	$ (0.12)
Weighted average shares outstanding and to be issued—
Basic and Diluted (in shares)	72,775,781	70,607,338

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Board of Directors [Member] Common Stock [Member]	Board of Directors [Member] Additional Paid-in Capital [Member]	Board of Directors [Member]	Consultant [Member] Common Stock [Member]	Consultant [Member] Additional Paid-in Capital [Member]	Consultant [Member] Retained Earnings [Member]	Consultant [Member] Noncontrolling Interest [Member]	Consultant [Member] Treasury Stock, Common [Member]	Consultant [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Treasury Stock, Common [Member]	Total
Balance (in shares) at Dec. 31, 2021										68,153,336
Balance at Dec. 31, 2021										$ 68,153	$ 124,915,560	$ (107,704,274)	$ (152,541)	$ (911,516)	$ 16,215,382
Stock based compensation											1,499,302	0	0		1,499,302
Common stock issued to be employee for bonus										$ 0	264,385	0	0	0	264,385
Common stock issued to employee for compensation (in shares)										30,196
Common stock issued to employee for compensation											39,973	0	0	0	40,003
Common stock to be issued for payment of consulting services (in shares)										577,074
Common stock to be issued for payment of consulting services										$ 577	746,774	0	0	0	747,351
Common stock to be issued to employees for bonuses (in shares)										147,338
Common stock to be issued to employees for bonuses										$ 147	(147)	0	0	0	0
Common stock issued for services (in shares)	398,553
Common stock issued for services	$ 399	$ 12,478	$ 12,877
Net loss												(8,706,131)	(66,735)		(8,772,866)
Balance (in shares) at Dec. 31, 2022										69,306,497
Balance at Dec. 31, 2022										$ 69,306	127,478,325	(116,410,405)	(219,276)	(911,516)	10,006,434
Stock based compensation											1,467,425				1,467,425
Common stock issued to employee for compensation										$ 0	417,500	0	0	0	417,500
Common stock issued for services (in shares)				1,051,660						758,683
Common stock issued for services				$ 1,051	$ 744,948	$ 0	$ 0	$ 0	$ 745,999	$ 759	(759)	0	0	0	0
Net loss												(6,929,104)	(51,843)	0	(6,980,947)
Common stock issued in public offering net of issuance cost of $431,849 (in shares)										4,765,000
Common stock issued in public offering net of issuance cost of $431,849										$ 4,765	2,565,336	0	0	0	2,570,101
Repurchase of noncontrolling interest										$ 0	(485,119)	0	271,119	0	(214,000)
Balance (in shares) at Dec. 31, 2023										75,881,840
Balance at Dec. 31, 2023										$ 75,881	$ 132,187,656	$ (123,339,509)	$ 0	$ (911,516)	$ 8,012,512

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Equity (Parentheticals)	12 Months Ended
	Dec. 31, 2023 USD ($)
Issuance costs	$ 431,849

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (6,980,947)	$ (8,772,866)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	12,999	14,180
Amortization of intangibles	49,320	49,663
Stock based compensation	1,467,426	1,499,302
Inventory Reserve	258,011	582,299
Employees paid in stock	417,500	317,265
Expense paid in stock	745,999	747,351
Unrealized gain on marketable securities	(9,282)	0
Bad debt expense	24,865	0
Amortization of right-of-use asset	88,450	80,533
Changes in operating assets and liabilities:
Decrease in accounts receivable	356,188	249,555
Increase in inventories	(1,103,861)	(833,121)
Increase in advances	(46,246)	(16,041)
Increase in prepaid expenses and other current assets	(73,912)	(68,512)
(Decrease) increase in accounts payable	(413,125)	322,300
(Decrease) increase in accounts payable, related party	(392,981)	407,636
Increase (decrease) in accrued expenses	386,882	(292,495)
(Decrease) in accrued expenses, related party	(30,361)	(246,692)
Decrease operating right of use lease asset	(83,054)	(72,353)
Net cash used in operating activities	(5,326,129)	(6,031,996)
Cash flows from investing activities:
Purchase of furniture, fixtures, and equipment	(4,881)	(8,527)
Sale of Marketable securities	4,966,213	0
Purchase of Marketable securities	(7,933,504)	0
Net cash provided by (used in) in investing activities	(2,972,172)	(8,527)
Cash flows from financing activities:
Net proceeds from issuance of Common Stock	2,570,101	0
Payments finance lease obligations	(9,366)	(8,544)
Net cash provided by (used in) financing activities	2,560,735	(8,544)
Net decrease in cash and cash equivalents	(5,737,566)	(6,049,067)
Cash and cash equivalents at beginning of period	8,715,279	14,764,346
Cash and cash equivalents at end of period	2,977,713	8,715,279
Supplemental non-cash disclosure of cash flow information:
Declared repurchase of noncontrolling interest	$ 214,000	$ 0

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Dec. 31, 2023
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	Item 9B. None.
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note A - Organization and Busin

Note A - Organization and Business	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE A ORGANIZATION AND BUSINESS All references in this report to “Milestone Scientific,” “us,” “our,” “we,” the “Company” or “Milestone” refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., and Milestone Innovations Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C ompuDent ; CompuMed ; CompuFlo ; DPS Dynamic Pressure Sensing technology ; Milestone Scientific ; the Milestone logo ; SafetyWand ; STA Single Tooth Anesthesia System ; and The Wand . Milestone Scientific was incorporated in the State of Delaware in August 1989. The Wand CompuDent , STA Single Tooth Anesthesia System CompuMed . CompuDent CompuMed June 2017, 510 CompuFlo We are in the process of meeting with medical facilities and device distributors within the United States, Middle East and Europe. Certain of our medical instruments have obtained European CE mark approval and can be marketed and sold in most European countries. In 2020, one not may

Note B - Liquidity and Uncertai

Note B - Liquidity and Uncertainties	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE B- LIQUIDITY AND UNCERTAINTIES The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one December 31, 2023, 2022, December 31, 2023, twelve December 31, 2023 2022, Management has prepared cashflow forecasts covering a period of 12 12 September 12, 2023 In addition to its employees, the Company relies on (i) distributors, agents, and third third may

Note C - Summary of Significant

Note C - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE C SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 1. Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"), and the applicable rules and regulations of the Securities and Exchange Commission (SEC) include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Innovations Inc.(wholly owned). All significant, intra-entity transactions and balances have been eliminated in the consolidation. Ownership interests in consolidated entities that are held by entities other than us are reported as noncontrolling interests in our consolidated balance sheets. Losses attributed to noncontrolling interests are reported separately in our consolidated statements of operations. During December 2023, 2. The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the inventory valuation, and cash flow assumptions going concern considerations. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known Actual results could differ from those estimates. 3. Revenue Recognition The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following five i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products directly to consumers in the United States and through a global distribution network that includes both exclusive and non-exclusive distribution agreements with related and third Revenue from product sales is recognized upon transfer of control of a product to a customer at a point in time, generally upon date of shipment. The Company has no E-Commerce As of January 3, 2023, third Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers’ return rights and the Company’s historical experience with returns and the amount of product in the distribution channel not The Company terminated its major U.S. distributor contract as of December 31, 2022. March 31, 2023. December 31, 2022 December 31, 2023 Financing and Payment The Company's payment terms differ by geography and customer, but payments from distributors are required within 90 third third two Disaggregation of Revenue The Company operates in two operating segments: dental and medical. Therefore, the results of the Company's operations are reported on a consolidated basis for the purposes of segment reporting, consistent with internal management reporting. See Note M for revenues by geographical market, based on the customer’s location, and product category for the years ended December 31, 2023 2022 5. Cash and Cash Equivalents Milestone Scientific considers all highly liquid investments purchased with an original maturity of three December 31, 2023 2022 December 31, 2023 2022 $250,000. 6. The Company’s marketable securities are comprised of treasury bills with an original maturity greater than three 2016 01. The appropriate classification of marketable securities is determined at the time of purchase and evaluated as of each reporting balance sheet date. Investments in marketable debt and equity securities classified as available-for-sale are reported at fair value. Fair value is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Declines in the fair values of equity securities that are considered other-than-temporary, are charged to other income (expense), net. The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. As of December 31, 2023 3 6 7. Accounts Receivable Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the ability or inability of its customers to make payments on amounts billed. Most credit sales are due within 90 not December 31, 2023 2022, 9. Inventories Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first The valuation allowance creates a new cost basis for the inventory, and it is not 10. Furniture, Fixture and Equipment Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from three seven 11. Intangible Assets Patents and Developed Technology Patents are recorded at cost to prepare and file the applicable documents with the United States Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity are recorded at acquisition cost and be amortized at the estimated useful life. Patent defense costs, to the extent applicable, are expensed as incurred. 12. Impairment of Long-Lived Assets Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not • significant under performance relative to expected historical or projected future operating results; • significant changes in the manner of our use of the acquired assets or the strategy for our overall business; • significant negative industry or economic trends; and • significant technological changes, which would render the technology obsolete. Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs. 13. Research and Development Research and development costs, which consist principally of new product development costs payable to third 14. Income Taxes Milestone Scientific accounts for income taxes under the asset and liability method which requires deferred tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. On December 31, 2023 2022, 2020, 2021, 2022 15. Basic and Diluted Net Loss Per Common Share Milestone Scientific presents “basic ”loss per common share applicable to common stockholders and, if applicable, “diluted” loss per common share applicable to common stockholders pursuant to the provisions of ASC 260, December 31, 2023 2022, Since Milestone Scientific had net losses in the years ended December 31, 2023 2022, not December 31, 2023 2022, 16. Fair Value of Financial Instruments Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company required us to classify fair value measurements in one ● Level 1 ● Level 2 1 ● Level 3 Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may December 31, 2023, Level 1 Level 2 Level 3 Total Marketable Securities December 31, 2023 $ 2,976,573 $ 2,976,573 Marketable Securities included US Treasury securities totaling $2,976,573 that are considered to be highly liquid and easily transferable at December 31, 2023. 1 The Company had no December 31, 2022. 17. Milestone Scientific accounts for stock-based compensation under ASC Topic 718, 718 18. The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480, 480” 815, 815” The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, 480, 815, not 19. Recent Accounting Pronouncements . Recently Issued Accounting Pronouncement In November 2023, 2023 07, Segment Reporting (Topic 280 2023 07 2023 07 280 2023 07 280. 2023 07 January 1, 2024, January 1, 2025. not 2023 07 In December 2023, 2023 09, Income Taxes (Topic 740 2023 09 five five 2023 09 January 1, 2025, not 2023 09 Recently Adopted Accounting Pronouncement In June 2016, 2016 13, Measurement of Credit Losses on Financial Instruments 2016 13” January 1, 2023, 2016 13, Measurement of Credit Losses on Financial Instruments 2016 13” not In November 2019, 2019 10, Financial Instruments - Credit Losses (Topic, 326 815 842 dates 2016 13 2019 10, 2016 13 December 15, 2022, January 1, 2023, 2019 10, Financial Instruments - Credit Losses (Topic, 326 815 842 not

Note D - Inventories

Note D - Inventories	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE D INVENTORIES December 31, 2023 December 31, 2022 Dental finished goods $ 2,404,970 $ 1,315,263 Medical finished goods 14,730 334,124 Component parts and other materials 218,486 142,948 Total inventories $ 2,638,186 $ 1,792,335 The Company has recorded an allowance on slow moving Medical finished goods due to the slow adoption of the epidural instruments and handpieces for approximately $258,000 and $582,000 as of December 31, 2023 2022,

Note E - Advances on Contracts

Note E - Advances on Contracts	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Advances to Contract Manufacturer [Text Block]	NOTE E ADVANCES ON CONTRACTS The advances on contracts represent funding of future dental STA "Single Tooth Anesthesia System" and epidural inventory purchases and epidural replacements parts. The balance of the advances as of December 31, 2023 2022 .

Note F - Furniture, Fixtures an

Note F - Furniture, Fixtures and Equipment	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE F FURNITURE, FIXTURES AND EQUIPMENT December 31, 2023 December 31, 2022 Leasehold improvements $ 24,734 $ 24,734 Office furniture and equipment 181,745 178,058 Molds 7,200 7,200 Trade show displays 151,462 151,462 Computers and software 281,256 280,066 Tooling Safety Wand 125,022 125,022 Tooling equipment-STA & Wand 11,100 11,100 EPI and IA Instruments 82,363 82,363 STA Trials Instruments $ 63,752 63,752 Total 928,634 923,757 Less accumulated depreciation (918,610 ) (905,611 ) Total $ 10,024 $ 18,146 Depreciation expenses was $12,999 and $14,180 for the years ended December 31, 2023, 2022,

Note G - Intangibles, Net

Note G - Intangibles, Net	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	NOTE G INTANGIBLES, NET December 31, 2023 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,199,227 ) $ 178,636 Total $ 1,377,863 $ (1,199,227 ) $ 178,636 December 31, 2022 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,149,907 ) $ 227,956 Total $ 1,377,863 $ (1,149,907 ) $ 227,956 Patents are amortized utilizing the straight-line method over estimated useful lives ranging from 3 to 20 years. Amortization expense was approximately $49,000 and $50,000 for the years ended December 31, 2023 2022, 2024 2027

Note H - Stockholders' Equity

Note H - Stockholders' Equity	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Equity [Text Block]	NOTE H STOCKHOLDERS EQUITY PUBLIC OFFERING On December 10, 2023, 45 NONCONTROLLING INTEREST During December 2023, no 805, Business Combinations 805" not 805. 810, Consolidation December 31, 2023, WARRANTS The following table summarizes information about shares issuable under warrants outstanding on December 31, 2023: Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2023 4,268,221 2.18 0.50 - Issued - - - - Exercised - - - - Expired or cancelled (3,953,649 ) - - - Outstanding and exercisable at December 31,2023 314,572 0.50 0.10 59,737 SHARES TO BE ISSUED As of December 31, 2023 2022, As of December 31, 2023 2022, The following table summarizes information about shares to be issued on December 31, 2023 2022. 2023 2022 Shares-to-be-issued, outstanding January 1, respectively 2,440,673 2,066,343 Granted in current period 658,244 524,814 Issued in current period - (150,484 ) Shares-to be issued outstanding December 31, respectively 3,098,917 2,440,673

Note I - Stock Option Plans

Note I - Stock Option Plans	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	NOTE I STOCK OPTION PLANS The Milestone Scientific Inc., Amended and Restated 2020 June 28, 2023 "2020 June 2031. may not three five December 31, 2023 2022, Milestone Scientific recognizes compensation expenses over the requisite service period and in the case of performance-based options over the period of the expected performance. For the years ended December 31, 2023 2022, As of December 31, 2023, A summary of option activity for employees under the plans and changes the year ended December 31, 2023 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2023 3,059,989 2.36 6.38 - Granted during 2023 - - - - Exercised during 2023 - - - - Forfeited or expired during 2023 (23,000 ) - - - Options outstanding December 31, 2023 3,036,989 2.29 5.41 - Exercisable, December 31, 2023 1,732,084 2.21 4.34 - There were no options granted to employees during the year ended December 31, 2023. A summary of option activity for non-employees under the plans and changes during the year ended December 31, 2023 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2023 91,663 1.75 2.55 1,083 Granted during 2023 8,333 0.89 4.21 - Exercised during 2023 (8,333 ) 0.75 - - Options outstanding December 31, 2023 91,663 1.76 2.25 2,833 Exercisable, December 31, 2023 83,332 1.86 1.79 2,833 The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. For the years ended December 31, 2023 2022, A summary of restricted stock under the plans and changes during the year ended December 31, 2023 Number of Shares Weighted Average Grant-Date Fair Value per Award Non-vested as January 1, 2023 435,293 1.18 Granted 617,978 0.89 Vested (694,658 ) - Cancelled (30,676 ) - Non-vested as December 31, 2023 327,937 0.91 As of December 31, 2023, December 31, 2023 2022, December 31, 2023, As of December 31, 2023, June 2023, first October 2023, January 2024, April 2024. December 31, 2023, December 31, 2023,

Note J - Employment Contract an

Note J - Employment Contract and Consulting Agreements	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Employment and Consulting Agreements [Text Block]	NOTE J EMPLOYMENT CONTRACT AND CONSULTING AGREEMENTS Consulting Agreements K. Tucker Andersen, a significant stockholder of Milestone Scientific, has an agreement with Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were $100,000 for years ended December 31, 2023 2022, The Director of Clinical Affairs’ royalty fee was approximately $485,000 and $442,000 for the years ended December 31, 2023 2022, December 31, 2023 2022, December 31, 2023, 2022, Employment Contracts On March 2, 2021, May 9, 2027, January 1, 2005 February 25, 2021, May 9, 2027, As part of the Succession Plan of the Company, Mr. Osser agreed, pursuant to an agreement dated April 6, 2021 ( July 2017 July 2017 one 280G 4 five ten May 19, 2021, Compensation under the Employment Agreement and the Consulting Agreement is payable for 9.5 May 19, 2021. December 31, 2023 2022, December 31, 2023 2022, On January 1, 2022, December 31, 2024, three three 3 thirty-three sixty-seven four two

Note K - Income Taxes

Note K - Income Taxes	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE K INCOME TAXES Milestone Scientific accounts for income taxes under the asset and liability method which requires deferred tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. At December 31, 2023 2022, no No 2020, 2021, 2022 Due to Milestone Scientific's history of operating losses, a full valuation allowances have been provided for all of Milestone Scientific's deferred tax assets. At December 31, 2023 2022, Deferred tax attributes resulting from differences between financial accounting amounts and tax bases of assets and liabilities at December 31, 2023 2022 2023 2022 Allowance for Doubtful Accounts 2,000 $ 2,000 Warranty Reserve - 2,000 Impaired Assets - - Capitalized Sec. 174 R&D 344,000 242,000 Inventory Reserve 300,000 242,000 Deferred Officer's Compensation 689,000 428,000 Depreciation and Amortization (44,000 ) (56,000 ) Right of Use Asset (86,000 ) (108,000 ) Lease Liability 93,000 116,000 Net Operating Loss Carryforwards 19,920,000 19,315,000 Tax Credits 558,000 688,000 Other 302,000 147,000 Subtotal 22,080,000 21,018,000 Valuation allowance (22,080,000 ) (21,018,000 ) Non-current deferred tax asset - - As of December 31, 2023 2022, December 31, 2023, December 31, 2017 December 2037. December 31, 2023, 2018 State net operating losses were approximately $63,300,000 and $60,500,000 for the periods ended December 31, 2023 2022, December 2041. The utilization of Milestone Scientific's net operating losses may 382 may Accounting for uncertainties in income taxes prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure, and transition. No interest and penalties are present for periods open. Tax returns for the 2020, 2021, 2022 A reconciliation of the statutory tax rates for the years ended December 31, 2023 2022 Statutory Rate 21.00 % 21.00 % State income tax - all states 0.88 % -2.74 % Stock compensation 0.58 % -2.57 % NOL Expiration -5.05 % -4.69 % Return to Provision -2.21 % 0.00 % Other 0.03 % -0.56 % Subtotal 15.23 % 10.44 % Valuation Allowance -15.23 % -10.44 % Effective tax Rate 0.00 % 0.00 %

Note L - Segment and Geographic

Note L - Segment and Geographic Data	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE L SEGMENT AND GEOGRAPHIC DATA The Company conducts its business through two not The following tables present information about our reportable and operating segments: Year ended December 31, Sales Net Sales: 2023 2022 Dental $ 9,761,444 $ 8,753,156 Medical 66,000 52,750 Total net sales $ 9,827,444 $ 8,805,906 Operating Income (Loss): 2023 2022 Dental $ 2,128,199 $ 1,121,815 Medical (3,708,170 ) (4,788,105 ) Corporate (5,526,503 ) (5,161,183 ) Total operating loss $ (7,106,474 ) $ (8,827,473 ) Depreciation and Amortization: 2023 2022 Dental $ 4,243 $ 3,805 Medical 2,787 4,075 Corporate 54,882 55,875 Total depreciation and amortization $ 61,912 $ 63,755 Income (loss) before taxes and equity in earnings of affiliates: 2023 2022 Dental $ 2,127,659 $ 1,116,598 Medical (3,708,170 ) (4,794,089 ) Corporate (5,400,436 ) (5,095,375 ) Total loss before taxes and equity in earnings of affiliate $ (6,980,947 ) $ (8,772,866 ) Total Assets December 31, 2023 December 31, 2022 Dental $ 4,866,786 $ 3,875,978 Medical 345,194 620,373 Corporate 6,159,532 9,205,735 Total assets $ 11,371,512 $ 13,702,086 The following table presents information about our operations by geographic area as of December 31, 2023 2022. 2023 Domestic: US Dental Medical Grand Total Instruments $ 1,002,697 $ 1,000 $ 1,003,697 Handpieces 4,270,898 12,000 4,282,898 Accessories 75,285 - 75,285 Grand Total $ 5,348,880 $ 13,000 $ 5,361,880 International: Rest of World Instruments $ 1,251,354 $ 25,000 $ 1,276,354 Handpieces 2,845,734 28,000 2,873,734 Accessories 45,476 - 45,476 Grand Total $ 4,142,564 $ 53,000 $ 4,195,564 International: China Instruments $ 270,000 $ - $ 270,000 Handpieces - - - Accessories - - - Grand Total $ 270,000 $ - $ 270,000 Total Product Sales $ 9,761,444 $ 66,000 $ 9,827,444 2022 Domestic: US Dental Medical Grand Total Instruments $ 524,715 $ 7,500 $ 532,215 Handpieces 2,653,914 25,250 2,679,164 Accessories 78,493 78,493 Grand Total $ 3,257,122 $ 32,750 $ 3,289,872 International: Rest of World Instruments $ 1,413,525 $ - $ 1,413,525 Handpieces 3,391,748 20,000 3,411,748 Accessories 60,797 - 60,797 Grand Total $ 4,866,070 $ 20,000 $ 4,886,070 International: China Instruments $ 270,000 $ - $ 270,000 Handpieces 359,964 - 359,964 Accessories - - - Grand Total $ 629,964 $ - $ 629,964 Total Product Sales $ 8,753,156 $ 52,750 $ 8,805,906

Note M - Concentrations

Note M - Concentrations	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE M-- CONCENTRATION Milestone Scientific has informal arrangements with third CompuDent CompuMed December 31, 2023 2022. On January 3, 2023, December 31,2023, two December 31, 2022. We had three December 31, 2023. two December 31, 2022. As of December 31, 2023 three one December 31, 2022.

Note N - Related Party Transact

Note N - Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE N -- RELATED PARTY TRANSACTIONS United Systems Milestone Scientific has a supply agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal supplier of its handpieces, pursuant to which it procures manufactured products under specific purchase orders, but without minimum purchase commitments. Purchases from this supplier were approximately 2.3 million and $3.4 million for the twelve December 31, 2023, 2022, December 31, 2023, December 31, 2022, June 2021, ten Other In December 31, 2023 2022 2021. K. Tucker Andersen, a significant stockholder of Milestone Scientific, has an agreement with Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were $100,000 for years ended December 31, 2023 2022, Director of Clinical Affairs The Director of Clinical Affairs’ royalty fee was approximately $485,000 and $442,000 for the years ended December 31, 2023 2022, December 31, 2023 2022, December 31, 2023, 2022, Director On March 2, 2021, May 9, 2027, January 1, 2005 February 25, 2021, May 9, 2027, As part of the Succession Plan of the Company, Mr. Osser agreed, pursuant to an agreement dated April 6, 2021 ( With respect to Mr. Osser’s July 2017 July 2017 one 280G 4 five ten May 19, 2021, Compensation under the Employment Agreement and the Consulting Agreement is payable for 9.5 May 19, 2021. December 31, 2023 2022, December 31, 2023 2022,

Note O - Commitments

Note O - Commitments	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE O COMMITMENTS ( 1 Contract Manufacturing Agreement Milestone Scientific has informal arrangements with third December 31, 2023, December 31, 2022, December 31, 2023 2022 ( 2 Leases Operating Leases In August 2019, not seven January 8, 2021. April 1, 2021, January 1 not As of December 31, 2023, December 31, 2023 December 31, 2022, December 31, 2022, The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: ● As the Company’s leases do not ● Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component. ● The expected lease terms include non-cancellable lease periods. Renewal option periods are not not The components of lease expense were as follows: December 31, 2023 December 31, 2022 Cash paid for operating lease liabilities $ 127,526 $ 127,995 Cash paid for finance lease liabilities 10,740 10,740 Right-of-use assets obtained in exchange for new operating lease liabilities (1) Property and equipment obtained in exchange for new finance lease liabilities Weighted Average Remaining Lease Term Finance leases (years) 1.04 years 2.04 years Operating leases (years) 3.25 years 4.25 years Weighted-average discount rate – operating leases Weighted-average discount rate – finance leases Maturity of lease liabilities as December 31, 2023 Operating Lease Finance Lease 2024 133,560 10,740 2025 136,343 433 2026 139,125 - 2027 35,477 - Less: Interest 444,505 11,173 Present Value of lease liabilities (59,225 ) (475 ) 385,280 10,698

Note P - Benefit Plan

Note P - Benefit Plan	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Retirement Benefits [Text Block]	NOTE P BENEFIT PLAN Milestone Scientific has a Defined Contribution Plan that allows eligible employees to contribute part of their salary through payroll deductions. Milestone Scientific does not not

Note Q - Subsequent Events

Note Q - Subsequent Events	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE Q SUBSEQUENT EVENTS In Connection with the Company's capital raise on December 10, 2023, January 12, 2024 Since the year ended December 31, 2023,

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	1. Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"), and the applicable rules and regulations of the Securities and Exchange Commission (SEC) include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Innovations Inc.(wholly owned). All significant, intra-entity transactions and balances have been eliminated in the consolidation. Ownership interests in consolidated entities that are held by entities other than us are reported as noncontrolling interests in our consolidated balance sheets. Losses attributed to noncontrolling interests are reported separately in our consolidated statements of operations. During December 2023,
Use of Estimates, Policy [Policy Text Block]	2. The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the inventory valuation, and cash flow assumptions going concern considerations. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known Actual results could differ from those estimates.
Revenue [Policy Text Block]	3. Revenue Recognition The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following five i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products directly to consumers in the United States and through a global distribution network that includes both exclusive and non-exclusive distribution agreements with related and third Revenue from product sales is recognized upon transfer of control of a product to a customer at a point in time, generally upon date of shipment. The Company has no E-Commerce As of January 3, 2023, third Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers’ return rights and the Company’s historical experience with returns and the amount of product in the distribution channel not The Company terminated its major U.S. distributor contract as of December 31, 2022. March 31, 2023. December 31, 2022 December 31, 2023 Financing and Payment The Company's payment terms differ by geography and customer, but payments from distributors are required within 90 third third two Disaggregation of Revenue The Company operates in two operating segments: dental and medical. Therefore, the results of the Company's operations are reported on a consolidated basis for the purposes of segment reporting, consistent with internal management reporting. See Note M for revenues by geographical market, based on the customer’s location, and product category for the years ended December 31, 2023 2022
Cash and Cash Equivalents, Policy [Policy Text Block]	5. Cash and Cash Equivalents Milestone Scientific considers all highly liquid investments purchased with an original maturity of three December 31, 2023 2022 December 31, 2023 2022 $250,000.
Marketable Securities, Policy [Policy Text Block]	6. The Company’s marketable securities are comprised of treasury bills with an original maturity greater than three 2016 01. The appropriate classification of marketable securities is determined at the time of purchase and evaluated as of each reporting balance sheet date. Investments in marketable debt and equity securities classified as available-for-sale are reported at fair value. Fair value is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Declines in the fair values of equity securities that are considered other-than-temporary, are charged to other income (expense), net. The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. As of December 31, 2023 3 6
Accounts Receivable [Policy Text Block]	7. Accounts Receivable Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the ability or inability of its customers to make payments on amounts billed. Most credit sales are due within 90 not December 31, 2023 2022,
Inventory, Policy [Policy Text Block]	9. Inventories Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first The valuation allowance creates a new cost basis for the inventory, and it is not
Property, Plant and Equipment, Policy [Policy Text Block]	10. Furniture, Fixture and Equipment Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from three seven
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	11. Intangible Assets Patents and Developed Technology Patents are recorded at cost to prepare and file the applicable documents with the United States Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity are recorded at acquisition cost and be amortized at the estimated useful life. Patent defense costs, to the extent applicable, are expensed as incurred.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	12. Impairment of Long-Lived Assets Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not • significant under performance relative to expected historical or projected future operating results; • significant changes in the manner of our use of the acquired assets or the strategy for our overall business; • significant negative industry or economic trends; and • significant technological changes, which would render the technology obsolete. Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs.
Research and Development Expense, Policy [Policy Text Block]	13. Research and Development Research and development costs, which consist principally of new product development costs payable to third
Income Tax, Policy [Policy Text Block]	14. Income Taxes Milestone Scientific accounts for income taxes under the asset and liability method which requires deferred tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. On December 31, 2023 2022, 2020, 2021, 2022
Earnings Per Share, Policy [Policy Text Block]	15. Basic and Diluted Net Loss Per Common Share Milestone Scientific presents “basic ”loss per common share applicable to common stockholders and, if applicable, “diluted” loss per common share applicable to common stockholders pursuant to the provisions of ASC 260, December 31, 2023 2022, Since Milestone Scientific had net losses in the years ended December 31, 2023 2022, not December 31, 2023 2022,
Fair Value of Financial Instruments, Policy [Policy Text Block]	16. Fair Value of Financial Instruments Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company required us to classify fair value measurements in one ● Level 1 ● Level 2 1 ● Level 3 Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may December 31, 2023, Level 1 Level 2 Level 3 Total Marketable Securities December 31, 2023 $ 2,976,573 $ 2,976,573 Marketable Securities included US Treasury securities totaling $2,976,573 that are considered to be highly liquid and easily transferable at December 31, 2023. 1 The Company had no December 31, 2022.
Share-Based Payment Arrangement [Policy Text Block]	17. Milestone Scientific accounts for stock-based compensation under ASC Topic 718, 718
Warrants [Policy Text Block]	18. The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480, 480” 815, 815” The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, 480, 815, not
New Accounting Pronouncements, Policy [Policy Text Block]	19. Recent Accounting Pronouncements . Recently Issued Accounting Pronouncement In November 2023, 2023 07, Segment Reporting (Topic 280 2023 07 2023 07 280 2023 07 280. 2023 07 January 1, 2024, January 1, 2025. not 2023 07 In December 2023, 2023 09, Income Taxes (Topic 740 2023 09 five five 2023 09 January 1, 2025, not 2023 09 Recently Adopted Accounting Pronouncement In June 2016, 2016 13, Measurement of Credit Losses on Financial Instruments 2016 13” January 1, 2023, 2016 13, Measurement of Credit Losses on Financial Instruments 2016 13” not In November 2019, 2019 10, Financial Instruments - Credit Losses (Topic, 326 815 842 dates 2016 13 2019 10, 2016 13 December 15, 2022, January 1, 2023, 2019 10, Financial Instruments - Credit Losses (Topic, 326 815 842 not

Note C - Summary of Significa_2

Note C - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Total Marketable Securities December 31, 2023 $ 2,976,573 $ 2,976,573

Note D - Inventories (Tables)

Note D - Inventories (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2023 December 31, 2022 Dental finished goods $ 2,404,970 $ 1,315,263 Medical finished goods 14,730 334,124 Component parts and other materials 218,486 142,948 Total inventories $ 2,638,186 $ 1,792,335

Note F - Furniture, Fixtures _2

Note F - Furniture, Fixtures and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2023 December 31, 2022 Leasehold improvements $ 24,734 $ 24,734 Office furniture and equipment 181,745 178,058 Molds 7,200 7,200 Trade show displays 151,462 151,462 Computers and software 281,256 280,066 Tooling Safety Wand 125,022 125,022 Tooling equipment-STA & Wand 11,100 11,100 EPI and IA Instruments 82,363 82,363 STA Trials Instruments $ 63,752 63,752 Total 928,634 923,757 Less accumulated depreciation (918,610 ) (905,611 ) Total $ 10,024 $ 18,146

Note G - Intangibles, Net (Tabl

Note G - Intangibles, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 31, 2023 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,199,227 ) $ 178,636 Total $ 1,377,863 $ (1,199,227 ) $ 178,636 December 31, 2022 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,149,907 ) $ 227,956 Total $ 1,377,863 $ (1,149,907 ) $ 227,956

Note H - Stockholders' Equity (

Note H - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2023 4,268,221 2.18 0.50 - Issued - - - - Exercised - - - - Expired or cancelled (3,953,649 ) - - - Outstanding and exercisable at December 31,2023 314,572 0.50 0.10 59,737
Deferred Compensation Arrangement with Individual, Share-based Payments [Table Text Block]	2023 2022 Shares-to-be-issued, outstanding January 1, respectively 2,440,673 2,066,343 Granted in current period 658,244 524,814 Issued in current period - (150,484 ) Shares-to be issued outstanding December 31, respectively 3,098,917 2,440,673

Note I - Stock Option Plans (Ta

Note I - Stock Option Plans (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2023 3,059,989 2.36 6.38 - Granted during 2023 - - - - Exercised during 2023 - - - - Forfeited or expired during 2023 (23,000 ) - - - Options outstanding December 31, 2023 3,036,989 2.29 5.41 - Exercisable, December 31, 2023 1,732,084 2.21 4.34 - Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2023 91,663 1.75 2.55 1,083 Granted during 2023 8,333 0.89 4.21 - Exercised during 2023 (8,333 ) 0.75 - - Options outstanding December 31, 2023 91,663 1.76 2.25 2,833 Exercisable, December 31, 2023 83,332 1.86 1.79 2,833
Restricted Stock [Member]
Notes Tables
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]	Number of Shares Weighted Average Grant-Date Fair Value per Award Non-vested as January 1, 2023 435,293 1.18 Granted 617,978 0.89 Vested (694,658 ) - Cancelled (30,676 ) - Non-vested as December 31, 2023 327,937 0.91

Note K - Income Taxes (Tables)

Note K - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2023 2022 Allowance for Doubtful Accounts 2,000 $ 2,000 Warranty Reserve - 2,000 Impaired Assets - - Capitalized Sec. 174 R&D 344,000 242,000 Inventory Reserve 300,000 242,000 Deferred Officer's Compensation 689,000 428,000 Depreciation and Amortization (44,000 ) (56,000 ) Right of Use Asset (86,000 ) (108,000 ) Lease Liability 93,000 116,000 Net Operating Loss Carryforwards 19,920,000 19,315,000 Tax Credits 558,000 688,000 Other 302,000 147,000 Subtotal 22,080,000 21,018,000 Valuation allowance (22,080,000 ) (21,018,000 ) Non-current deferred tax asset - -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2023 2022 Statutory Rate 21.00 % 21.00 % State income tax - all states 0.88 % -2.74 % Stock compensation 0.58 % -2.57 % NOL Expiration -5.05 % -4.69 % Return to Provision -2.21 % 0.00 % Other 0.03 % -0.56 % Subtotal 15.23 % 10.44 % Valuation Allowance -15.23 % -10.44 % Effective tax Rate 0.00 % 0.00 %

Note L - Segment and Geograph_2

Note L - Segment and Geographic Data (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year ended December 31, Sales Net Sales: 2023 2022 Dental $ 9,761,444 $ 8,753,156 Medical 66,000 52,750 Total net sales $ 9,827,444 $ 8,805,906 Operating Income (Loss): 2023 2022 Dental $ 2,128,199 $ 1,121,815 Medical (3,708,170 ) (4,788,105 ) Corporate (5,526,503 ) (5,161,183 ) Total operating loss $ (7,106,474 ) $ (8,827,473 ) Depreciation and Amortization: 2023 2022 Dental $ 4,243 $ 3,805 Medical 2,787 4,075 Corporate 54,882 55,875 Total depreciation and amortization $ 61,912 $ 63,755 Income (loss) before taxes and equity in earnings of affiliates: 2023 2022 Dental $ 2,127,659 $ 1,116,598 Medical (3,708,170 ) (4,794,089 ) Corporate (5,400,436 ) (5,095,375 ) Total loss before taxes and equity in earnings of affiliate $ (6,980,947 ) $ (8,772,866 ) Total Assets December 31, 2023 December 31, 2022 Dental $ 4,866,786 $ 3,875,978 Medical 345,194 620,373 Corporate 6,159,532 9,205,735 Total assets $ 11,371,512 $ 13,702,086
Sales by Product and by Geographical Region [Table Text Block]	2023 Domestic: US Dental Medical Grand Total Instruments $ 1,002,697 $ 1,000 $ 1,003,697 Handpieces 4,270,898 12,000 4,282,898 Accessories 75,285 - 75,285 Grand Total $ 5,348,880 $ 13,000 $ 5,361,880 International: Rest of World Instruments $ 1,251,354 $ 25,000 $ 1,276,354 Handpieces 2,845,734 28,000 2,873,734 Accessories 45,476 - 45,476 Grand Total $ 4,142,564 $ 53,000 $ 4,195,564 International: China Instruments $ 270,000 $ - $ 270,000 Handpieces - - - Accessories - - - Grand Total $ 270,000 $ - $ 270,000 Total Product Sales $ 9,761,444 $ 66,000 $ 9,827,444 2022 Domestic: US Dental Medical Grand Total Instruments $ 524,715 $ 7,500 $ 532,215 Handpieces 2,653,914 25,250 2,679,164 Accessories 78,493 78,493 Grand Total $ 3,257,122 $ 32,750 $ 3,289,872 International: Rest of World Instruments $ 1,413,525 $ - $ 1,413,525 Handpieces 3,391,748 20,000 3,411,748 Accessories 60,797 - 60,797 Grand Total $ 4,866,070 $ 20,000 $ 4,886,070 International: China Instruments $ 270,000 $ - $ 270,000 Handpieces 359,964 - 359,964 Accessories - - - Grand Total $ 629,964 $ - $ 629,964 Total Product Sales $ 8,753,156 $ 52,750 $ 8,805,906

Note O - Commitments (Tables)

Note O - Commitments (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Lease, Cost and Other Information [Table Text Block]	December 31, 2023 December 31, 2022 Cash paid for operating lease liabilities $ 127,526 $ 127,995 Cash paid for finance lease liabilities 10,740 10,740 Right-of-use assets obtained in exchange for new operating lease liabilities (1) Property and equipment obtained in exchange for new finance lease liabilities Weighted Average Remaining Lease Term Finance leases (years) 1.04 years 2.04 years Operating leases (years) 3.25 years 4.25 years Weighted-average discount rate – operating leases Weighted-average discount rate – finance leases
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Maturity of lease liabilities as December 31, 2023 Operating Lease Finance Lease 2024 133,560 10,740 2025 136,343 433 2026 139,125 - 2027 35,477 - Less: Interest 444,505 11,173 Present Value of lease liabilities (59,225 ) (475 ) 385,280 10,698

Note A - Organization and Bus_2

Note A - Organization and Business (Details Textual)	Dec. 31, 2023
Number of Countries in which Entity Operates	60

Note B - Liquidity and Uncert_2

Note B - Liquidity and Uncertainties (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Retained Earnings (Accumulated Deficit)	$ (123,339,509)	$ (116,410,405)
Operating Income (Loss)	(7,106,474)	(8,827,473)
Cash, Cash Equivalents, and Marketable Securities	6,000,000
Working Capital	7,700,000
Net Cash Provided by (Used in) Operating Activities	$ (5,326,129)	$ (6,031,996)

Note C - Summary of Significa_3

Note C - Summary of Significant Accounting Policies (Details Textual)	1 Months Ended	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares
Payments for Repurchase of Redeemable Noncontrolling Interest	$ 214,000
Allowance for Sales Returns		$ 0	$ 179,000
Number of Operating Segments		2
Marketable Securities, Current	2,976,573	$ 2,976,573	0
Accounts Receivable, Allowance for Credit Loss	10,000	10,000	10,000
Unrecognized Tax Benefits	0	0	0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense		$ 0	$ 0
Weighted Average Number of Shares Outstanding, Basic (in shares) | shares		72,775,781	70,607,338
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares		3,771,151	7,855,160
Marketable Securities	$ 2,976,573	$ 2,976,573
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years	3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years	7 years
US Treasury Securities [Member]
Marketable Securities, Current	$ 3,000,000	$ 3,000,000
Money Market Funds [Member]
Cash Equivalents, at Carrying Value	$ 3,000,000	$ 3,000,000	$ 8,700,000

Note C - Summary of Significa_4

Note C - Summary of Significant Accounting Policies - Fair Value of Marketable Securities (Details)	Dec. 31, 2023 USD ($)
Marketable Securities	$ 2,976,573
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Marketable Securities	2,976,573
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Marketable Securities	$ 2,976,573

Note D - Inventories (Details T

Note D - Inventories (Details Textual) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Slow Moving Medical Finished Goods [Member]
Inventory Valuation Reserves	$ 258,000	$ 582,000

Note D - Inventories - Summary

Note D - Inventories - Summary of Inventories (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Component parts and other materials	$ 218,486	$ 142,948
Total inventories	2,638,186	1,792,335
Dental Segment [Member]
Finished goods, net	2,404,970	1,315,263
Medical Segment [Member]
Finished goods, net	$ 14,730	$ 334,124

Note E - Advances on Contracts

Note E - Advances on Contracts (Details Textual) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Advances on Inventory Purchases	$ 1,371,548	$ 1,325,301

Note F - Furniture, Fixtures _3

Note F - Furniture, Fixtures and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Depreciation	$ 12,999	$ 14,180

Note F - Furniture, Fixtures _4

Note F - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Total	$ 10,024	$ 18,146
Leasehold Improvements [Member]
Furniture, fixtures and equipment	24,734	24,734
Office Furniture and Equipment [Member]
Furniture, fixtures and equipment	181,745	178,058
Tools, Dies and Molds [Member]
Furniture, fixtures and equipment	7,200	7,200
Trade Show Displays [Member]
Furniture, fixtures and equipment	151,462	151,462
Computer and Software [Member]
Furniture, fixtures and equipment	281,256	280,066
Tooling Safety Wand [Member]
Furniture, fixtures and equipment	125,022	125,022
Tooling Equipment - STA and Wand [Member]
Furniture, fixtures and equipment	11,100	11,100
EPI and IA Instruments [Member]
Furniture, fixtures and equipment	82,363	82,363
STA Trials Instruments [Member]
Furniture, fixtures and equipment	63,752	63,752
Furniture and Fixtures [Member]
Furniture, fixtures and equipment	928,634	923,757
Less accumulated depreciation	(918,610)	(905,611)
Total	$ 10,024	$ 18,146

Note G - Intangibles, Net (Deta

Note G - Intangibles, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Amortization of Intangible Assets	$ 49,320	$ 49,663
Finite-Lived Intangible Asset, Expected Amortization, Year One	34,000
Finite-Lived Intangible Asset, Expected Amortization, Year Two	28,000
Finite-Lived Intangible Asset, Expected Amortization, Year Three	28,000
Finite-Lived Intangible Asset, Expected Amortization, Year Four	86,000
Patents [Member]
Amortization of Intangible Assets	$ 49,000	$ 50,000
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		3 years
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		20 years

Note G - Intangibles, Net - Sum

Note G - Intangibles, Net - Summary of Patents (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Patents, cost	$ 1,377,863	$ 1,377,863
Patents, accumulated amortization	(1,199,227)	(1,149,907)
Patents-foundation intellectual property	178,636	227,956
Foundation Intellectual Property Patents [Member]
Patents, cost	1,377,863	1,377,863
Patents, accumulated amortization	(1,199,227)	(1,149,907)
Patents-foundation intellectual property	$ 178,636	$ 227,956

Note H - Stockholders' Equity_2

Note H - Stockholders' Equity (Details Textual) - USD ($)		12 Months Ended
	Dec. 10, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Proceeds from Issuance of Common Stock		$ 2,570,101	$ 0
Repurchase of Noncontrolling Interest		$ (214,000)
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)		3,098,917	2,440,673	2,066,343
Chief Executive Officer, Chief Financial Officer and Employees [Member]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)		2,571,292	2,057,976
Non-Employees [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		527,625	382,697
Additional Paid-in Capital [Member]
Repurchase of Noncontrolling Interest		$ (485,119)
Milestone Medical Inc. [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 214,000
Milestone Medical Inc. [Member] | Additional Paid-in Capital [Member]
Repurchase of Noncontrolling Interest		$ 485,000
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	4,765,000
Shares Issued, Price Per Share (in dollars per share)	$ 0.63
Proceeds from Issuance of Common Stock	$ 2.6
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)	714,750

Note H - Stockholders' Equity -

Note H - Stockholders' Equity - Warrants (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Outstanding (in shares)	4,268,221
Outstanding (in dollars per share)	$ 2.18
Outstanding (Year)	1 month 6 days	6 months
Issued, number of shares (in shares)	0
Issued, weighted average exercise price (in dollars per share)	$ 0
Exercised, number of shares (in shares)	0
Exercised, weighted average exercise price (in dollars per share)	$ 0
Expired or cancelled, number of shares (in shares)	(3,953,649)
Expired or cancelled, weighted average exercise price (in dollars per share)	$ 0
Outstanding (in shares)	314,572	4,268,221
Outstanding (in dollars per share)	$ 0.5	$ 2.18
Outstanding	$ 59,737

Note H - Stockholders' Equity_3

Note H - Stockholders' Equity - Summary of Shares to be Issued (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Shares-to-be-issued, outstanding (in shares)	2,440,673	2,066,343
Granted in current period (in shares)	658,244	524,814
Issued in current period (in shares)	0	(150,484)
Shares-to be issued outstanding December 31, respectively (in shares)	3,098,917	2,440,673

Note I - Stock Option Plans (De

Note I - Stock Option Plans (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Jun. 28, 2023	Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)	3,098,917	2,440,673		2,066,343
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Amount Capitalized	$ 900,000	$ 1,000,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 1,500,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years 3 months 18 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	0
Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	8,333
Share-Based Payment Arrangement, Expense	$ 19,700	22,900
Restricted Stock [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 2,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 months 15 days
Share-Based Payment Arrangement, Expense	$ (15,000)	$ (20,000)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	617,978
Restricted Stock [Member] | Territory Manager [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		2 years
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)	18,947
Restricted Stock [Member] | Board of Directors [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 132,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	3 months
Share-Based Payment Arrangement, Expense	$ 576,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	617,978
Share Price (in dollars per share)	$ 0.89
Restricted Stock [Member] | Board of Directors [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage	25%
Restricted Stock [Member] | Board of Directors [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage	25%
The 2020 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)		4,000,000	11,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	5 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	9,174,520	323,190

Note I - Stock Option Plans - S

Note I - Stock Option Plans - Summary of Option Activity for Employees (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Jan. 01, 2023
Number of options granted (in shares)	0
Share-Based Payment Arrangement, Employee [Member]
Number of options (in shares)	3,059,989
Weighted average exercise price, outstanding (in dollars per share)	$ 2.36
Weighted average remaining contractual life, outstanding (Year)	5 years 4 months 28 days	6 years 4 months 17 days
Aggregate intrinsic value, outstanding	$ 0
Number of options granted (in shares)	0
Weighted average exercise price, granted (in dollars per share)	$ 0
Number of options exercised (in shares)	0
Weighted average exercise price, exercised (in dollars per share)	$ 0
Number of options forfeited and expired (in shares)	(23,000)
Weighted average exercise price, forfeited or expired (in dollars per share)	$ 0
Number of options (in shares)	3,036,989	3,059,989
Weighted average exercise price, outstanding (in dollars per share)	$ 2.29	$ 2.36
Number of options exercisable (in shares)	1,732,084
Weighted average exercise price, exercisable (in dollars per share)	$ 2.21
Weighted average remaining contractual life, exercisable (Year)	4 years 4 months 2 days
Share-Based Payment Arrangement, Nonemployee [Member]
Number of options (in shares)	91,663
Weighted average exercise price, outstanding (in dollars per share)	$ 1.75
Weighted average remaining contractual life, outstanding (Year)	2 years 3 months	2 years 6 months 18 days
Aggregate intrinsic value, outstanding	$ 2,833		$ 1,083
Number of options granted (in shares)	8,333
Weighted average exercise price, granted (in dollars per share)	$ 0.89
Number of options exercised (in shares)	(8,333)
Weighted average exercise price, exercised (in dollars per share)	$ 0.75
Number of options (in shares)	91,663	91,663
Weighted average exercise price, outstanding (in dollars per share)	$ 1.76	$ 1.75
Number of options exercisable (in shares)	83,332
Weighted average exercise price, exercisable (in dollars per share)	$ 1.86
Weighted average remaining contractual life, exercisable (Year)	1 year 9 months 14 days
Weighted average remaining contractual life, granted (Year)	4 years 2 months 15 days
Aggregate intrinsic value, exercisable	$ 2,833

Note I - Stock Option Plans -_2

Note I - Stock Option Plans - Schedule of Restricted Stock (Details) - Restricted Stock [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Non-vested as January 1, 2023 (in shares)	435,293
Non-vested as January 1, 2023 (in dollars per share) | $ / shares	$ 1.18
Granted, Shares (in shares)	617,978
Granted, Weighted Average Grant-Date Fair Value per Award (in dollars per share) | $ / shares	$ 0.89
Vested, Shares (in shares)	(694,658)
Cancelled, Shares (in shares)	(30,676)
Non-vested, Shares (in shares)	327,937
Non-vested, Weighted Average Grant-Date Fair Value per Award (in dollars per share) | $ / shares	$ 0.91

Note J - Employment Contract _2

Note J - Employment Contract and Consulting Agreements (Details Textual) - USD ($)				1 Months Ended	12 Months Ended
	Jan. 01, 2022	Apr. 06, 2021	Jul. 10, 2017	Jul. 31, 2017	Dec. 31, 2023	Dec. 31, 2022	Mar. 02, 2021	Feb. 25, 2021
Director of Clinical Affairs [Member]
Royalty Expense					$ 485,000	$ 442,000
Professional Fees					156,000	154,000
Interim Chief Executive Officer [Member]
Royalty on Net Sales, Percentage							2.50%	5%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		5 years
Previous President and Chief Executive Officer [Member]
Increase (Decrease) in Deferred Compensation			$ (100,000)	$ (100,000)
Employment Agreement, Base Compensation			200,000	200,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		5 years
Deferred Compensation Arrangement with Individual, Compensation Expense					200,000	200,000
Consultant [Member]
Increase (Decrease) in Deferred Compensation			(100,000)	100,000
Employment Agreement, Base Compensation			$ 200,000	$ 200,000
Deferred Compensation Arrangement with Individual, Compensation Expense					200,000	200,000
Mr Osser [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		2,000,000
President and Chief Executive Officer [Member]
Base Annual Salary	$ 350,000
Bonus Compensation	400,000
Performance Based Bonuses	$ 100,000
Bonus Compensation Percent	33%
Share Bonus Compensation Percentage	67%
Related Party [Member] | Director of Clinical Affairs [Member]
Accounts Payable and Accrued Liabilities, Current					114,000	120,000
Consulting Services [Member] | Related Party [Member]
Costs and Expenses					$ 100,000	$ 100,000

Note K - Income Taxes (Details

Note K - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Loss Carryforwards, Valuation Allowance	$ 0	$ 0
Percentage of Valuation Allowance	100%
Unrecognized Tax Benefits	$ 0	0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	0	0
Domestic Tax Authority [Member]
Operating Loss Carryforwards	74,500,000	71,700,000
Operating Loss Carryforwards Subject to Expiration	38,100,000
Operating Loss Carryforwards, Indefinite Lived	$ 36,400,000
Open Tax Year	2020 2021 2022
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 63,300,000	$ 60,500,000

Note K - Income Taxes - Deferre

Note K - Income Taxes - Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Allowance for Doubtful Accounts	$ 2,000	$ 2,000
Warranty Reserve	0	2,000
Impaired Assets	0	0
Capitalized Sec. 174 R&D	344,000	242,000
Inventory Reserve	300,000	242,000
Deferred Officer's Compensation	689,000	428,000
Depreciation and Amortization	(44,000)	(56,000)
Right of Use Asset	(86,000)	(108,000)
Lease Liability	93,000	116,000
Net Operating Loss Carryforwards	19,920,000	19,315,000
Tax Credits	558,000	688,000
Other	302,000	147,000
Subtotal	22,080,000	21,018,000
Valuation allowance	(22,080,000)	(21,018,000)
Non-current deferred tax asset	$ 0	$ 0

Note K - Income Taxes - Reconci

Note K - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statutory Rate	21%	21%
State income tax - all states	0.88%	(2.74%)
Stock compensation	0.58%	(2.57%)
NOL Expiration	(5.05%)	(4.69%)
Return to Provision	(2.21%)	0%
Other	0.03%	(0.56%)
Subtotal	15.23%	10.44%
Valuation Allowance	(15.23%)	(10.44%)
Effective tax Rate	0%	0%

Note L - Segment and Geograph_3

Note L - Segment and Geographic Data (Details Textual)	12 Months Ended
	Dec. 31, 2023
Number of Reportable Segments	2

Note L - Segment and Geograph_4

Note L - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Product sales, net	$ 9,827,444	$ 8,805,906
Operating Income (Loss)	(7,106,474)	(8,827,473)
Depreciation and Amortization	61,912	63,755
Income (loss) before taxes and equity in earnings of affiliates	(6,980,947)	(8,772,866)
Total assets	11,371,512	13,702,086
Corporate, Non-Segment [Member]
Operating Income (Loss)	(5,526,503)	(5,161,183)
Depreciation and Amortization	54,882	55,875
Income (loss) before taxes and equity in earnings of affiliates	(5,400,436)	(5,095,375)
Total assets	6,159,532	9,205,735
Dental Segment [Member]
Product sales, net	9,761,444	8,753,156
Dental Segment [Member] | Operating Segments [Member]
Product sales, net	9,761,444	8,753,156
Operating Income (Loss)	2,128,199	1,121,815
Depreciation and Amortization	4,243	3,805
Income (loss) before taxes and equity in earnings of affiliates	2,127,659	1,116,598
Total assets	4,866,786	3,875,978
Medical Segment [Member]
Product sales, net	66,000	52,750
Medical Segment [Member] | Operating Segments [Member]
Product sales, net	66,000	52,750
Operating Income (Loss)	(3,708,170)	(4,788,105)
Depreciation and Amortization	2,787	4,075
Income (loss) before taxes and equity in earnings of affiliates	(3,708,170)	(4,794,089)
Total assets	$ 345,194	$ 620,373

Note L - Segment and Geograph_5

Note L - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Product sales, net	$ 9,827,444	$ 8,805,906
Product sales, net	9,827,444	8,805,906
Dental Segment [Member]
Product sales, net	9,761,444	8,753,156
Product sales, net	9,761,444	8,753,156
Medical Segment [Member]
Product sales, net	66,000	52,750
Product sales, net	66,000	52,750
Domestic [Member]
Product sales, net	5,361,880	3,289,872
Product sales, net	5,361,880	3,289,872
Domestic [Member] | Dental Segment [Member]
Product sales, net	5,348,880	3,257,122
Product sales, net	5,348,880	3,257,122
Domestic [Member] | Medical Segment [Member]
Product sales, net	13,000	32,750
Product sales, net	13,000	32,750
Rest of World [Member]
Product sales, net	4,195,564	4,886,070
Product sales, net	4,195,564	4,886,070
Rest of World [Member] | Dental Segment [Member]
Product sales, net	4,142,564	4,866,070
Product sales, net	4,142,564	4,866,070
Rest of World [Member] | Medical Segment [Member]
Product sales, net	53,000	20,000
Product sales, net	53,000	20,000
CHINA
Product sales, net	270,000	629,964
Product sales, net	270,000	629,964
CHINA | Dental Segment [Member]
Product sales, net	270,000	629,964
Product sales, net	270,000	629,964
CHINA | Medical Segment [Member]
Product sales, net	0	0
Product sales, net	0	0
CHINA | Instruments [Member]
Product sales, net	270,000
Product sales, net	270,000
Instruments [Member] | Domestic [Member]
Product sales, net	1,003,697	532,215
Product sales, net	1,003,697	532,215
Instruments [Member] | Domestic [Member] | Dental Segment [Member]
Product sales, net	1,002,697	524,715
Product sales, net	1,002,697	524,715
Instruments [Member] | Domestic [Member] | Medical Segment [Member]
Product sales, net	1,000	7,500
Product sales, net	1,000	7,500
Instruments [Member] | Rest of World [Member]
Product sales, net	1,276,354	1,413,525
Product sales, net	1,276,354	1,413,525
Instruments [Member] | Rest of World [Member] | Dental Segment [Member]
Product sales, net	1,251,354	1,413,525
Product sales, net	1,251,354	1,413,525
Instruments [Member] | Rest of World [Member] | Medical Segment [Member]
Product sales, net	25,000	0
Product sales, net	25,000	0
Instruments [Member] | CHINA
Product sales, net		270,000
Product sales, net		270,000
Instruments [Member] | CHINA | Dental Segment [Member]
Product sales, net	270,000	270,000
Product sales, net	270,000	270,000
Instruments [Member] | CHINA | Medical Segment [Member]
Product sales, net	0	0
Product sales, net	0	0
Handpieces [Member] | Domestic [Member]
Product sales, net	4,282,898	2,679,164
Product sales, net	4,282,898	2,679,164
Handpieces [Member] | Domestic [Member] | Dental Segment [Member]
Product sales, net	4,270,898	2,653,914
Product sales, net	4,270,898	2,653,914
Handpieces [Member] | Domestic [Member] | Medical Segment [Member]
Product sales, net	12,000	25,250
Product sales, net	12,000	25,250
Handpieces [Member] | Rest of World [Member]
Product sales, net	2,873,734	3,411,748
Product sales, net	2,873,734	3,411,748
Handpieces [Member] | Rest of World [Member] | Dental Segment [Member]
Product sales, net	2,845,734	3,391,748
Product sales, net	2,845,734	3,391,748
Handpieces [Member] | Rest of World [Member] | Medical Segment [Member]
Product sales, net	28,000	20,000
Product sales, net	28,000	20,000
Handpieces [Member] | CHINA
Product sales, net		359,964
Product sales, net		359,964
Handpieces [Member] | CHINA | Dental Segment [Member]
Product sales, net	0	359,964
Product sales, net	0	359,964
Handpieces [Member] | CHINA | Medical Segment [Member]
Product sales, net	0	0
Product sales, net	0	0
Accessories [Member] | Domestic [Member]
Product sales, net	75,285	78,493
Product sales, net	75,285	78,493
Accessories [Member] | Domestic [Member] | Dental Segment [Member]
Product sales, net	75,285	78,493
Product sales, net	75,285	78,493
Accessories [Member] | Domestic [Member] | Medical Segment [Member]
Product sales, net	0
Product sales, net	0
Accessories [Member] | Rest of World [Member]
Product sales, net	45,476	60,797
Product sales, net	45,476	60,797
Accessories [Member] | Rest of World [Member] | Dental Segment [Member]
Product sales, net	45,476	60,797
Product sales, net	45,476	60,797
Accessories [Member] | Rest of World [Member] | Medical Segment [Member]
Product sales, net	0	0
Product sales, net	0	0
Accessories [Member] | CHINA
Product sales, net	0	0
Product sales, net	0	0
Accessories [Member] | CHINA | Dental Segment [Member]
Product sales, net	0	0
Product sales, net	$ 0	0
Accessories [Member] | CHINA | Medical Segment [Member]
Product sales, net		0
Product sales, net		$ 0

Note M - Concentrations (Detail

Note M - Concentrations (Details Textual)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Number of Distributors		2
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | E-Commerce [Member]
Concentration Risk, Percentage	48%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Distributor One [Member]
Concentration Risk, Percentage		32%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Distributor Two [Member]
Concentration Risk, Percentage		11%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Number of Distributors	3	2
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributor One [Member]
Concentration Risk, Percentage	39%	33%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributor Two [Member]
Concentration Risk, Percentage	38%	20%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributor Three [Member]
Concentration Risk, Percentage	15%
Accounts Payable [Member] | Supplier Concentration Risk [Member] | Related Party [Member]
Number of Vendors	3	1
Accounts Payable [Member] | Supplier Concentration Risk [Member] | Vendor One [Member] | Related Party [Member]
Concentration Risk, Percentage	37%	42%
Accounts Payable [Member] | Supplier Concentration Risk [Member] | Vendor Two [Member] | Related Party [Member]
Concentration Risk, Percentage	17%
Accounts Payable [Member] | Supplier Concentration Risk [Member] | Vendor Three [Member] | Related Party [Member]
Concentration Risk, Percentage	12%

Note N - Related Party Transa_2

Note N - Related Party Transactions (Details Textual) - USD ($)			1 Months Ended	12 Months Ended
	Apr. 06, 2021	Jul. 10, 2017	Jul. 31, 2017	Dec. 31, 2023	Dec. 31, 2022	Mar. 02, 2021	Mar. 01, 2021	Feb. 25, 2021
Previous President and Chief Executive Officer [Member]
Increase (Decrease) in Deferred Compensation		$ (100,000)	$ (100,000)
Employment Agreement, Base Compensation		200,000	200,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	5 years
Deferred Compensation Arrangement with Individual, Compensation Expense				$ 200,000	$ 200,000
Consultant [Member]
Increase (Decrease) in Deferred Compensation		(100,000)	100,000
Employment Agreement, Base Compensation		$ 200,000	$ 200,000
Deferred Compensation Arrangement with Individual, Compensation Expense				200,000	200,000
Interim Chief Executive Officer [Member]
Royalty on Net Sales, Percentage						2.50%		5%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	5 years
Managing Director, China Operations [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense				200,000	200,000
Milestone China [Member] | Instruments [Member]
Revenues				270,000	630,000
Director Clinical Affair [Member]
Royalty Expense				485,000	442,000
Professional Fees				156,000	154,000
Royalty on Net Sales, Percentage						2.50%	5%
Director of Clinical Affairs [Member]
Accounts Payable and Accrued Liabilities, Current				114,000	120,000
Interim Chief Executive Officer [Member]
Royalty on Net Sales, Percentage						2.50%
Manufacturing Agreement for Handpieces [Member]
Related Party Transaction, Purchases from Related Party				2,300,000	3,400,000
Manufacturing Agreement for Handpieces [Member] | Related Party [Member] | Accounts Payable, Related Parties, Current [Member]
Accounts Payable and Accrued Liabilities				402,000	819,000
Consulting Services [Member] | Related Party [Member]
Costs and Expenses				$ 100,000	$ 100,000

Note O - Commitments (Details T

Note O - Commitments (Details Textual)	1 Months Ended	12 Months Ended
	Aug. 31, 2019 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jan. 08, 2021
Advances on Inventory Purchases		$ 1,371,548	$ 1,325,301
Finance Lease, Right-of-Use Asset, after Accumulated Amortization		8,998	17,645
Finance Lease, Liability		10,698	20,063
Finance Lease, Liability, Current		10,264	9,365
Finance Lease, Liability, Noncurrent		434	10,698
Operating Lease, Right-of-Use Asset		355,235	443,685
Operating Lease, Liability		385,280	476,980
Operating Lease, Liability, Current		103,427	91,701
Operating Lease, Liability, Noncurrent		$ 281,853	385,279
Office Lease for Headquarter in Roseland, New Jersey [Member]
Lessee, Operating Lease, Term of Contract (Year)				7 years
Lessee, Operating Lease, Electric Charge Per Square Foot	$ 2
Lessee, Operating Lease, Electric Payments, Annually	11,130
Office Lease for Headquarter in Roseland, New Jersey [Member] | Minimum [Member]
Operating Leases, Monthly Rent Expense	9,275
Office Lease for Headquarter in Roseland, New Jersey [Member] | Maximum [Member]
Operating Leases, Monthly Rent Expense	$ 10,898
Purchase Commitment for Devices [Member]
Purchase Commitment Number Of Units		2,200
Purchase Commitment, Remaining Minimum Amount Committed		$ 2,300,000	1,700,000
Advances on Inventory Purchases		1,300,000	1,200,000
Purchase Commitment For Devices Beginning In 2021 [Member]
Advances on Inventory Purchases		$ 76,000	$ 76,000

Note O - Commitments - Lease Ex

Note O - Commitments - Lease Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash paid for operating lease liabilities	$ 127,526	$ 127,995
Cash paid for finance lease liabilities	$ 10,740	$ 10,740
Finance leases (years) (Year)	1 year 14 days	2 years 14 days
Operating leases (years) (Year)	3 years 3 months	4 years 3 months

Note O - Commitments - Maturiti

Note O - Commitments - Maturities of Lease Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
2024, Operating Leases	$ 133,560
2024, Finance Leases	10,740
2025, Operating Leases	136,343
2025, Finance Leases	433
2026, Operating Leases	139,125
2026, Finance Leases	0
2027, Operating Leases	35,477
2027, Finance Leases	0
Less: Interest	444,505
Less: Interest	11,173
Present Value of lease liabilities	(59,225)
Present Value of lease liabilities	(475)
Operating Lease, Liability	385,280	$ 476,980
Finance Lease, Liability	$ 10,698	$ 20,063

Note Q - Subsequent Events (Det

Note Q - Subsequent Events (Details Textual) - USD ($)			1 Months Ended	12 Months Ended
	Jan. 12, 2024	Dec. 10, 2023	Jan. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Proceeds from Issuance of Common Stock				$ 2,570,101	$ 0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.5	$ 2.18
Subsequent Event [Member]
Stock Issued During Period Shares, Warrants Exercised (in shares)			103,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.5
Proceeds from Warrant Exercises			$ 51,647
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)		714,750
Over-Allotment Option [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	372,110
Proceeds from Issuance of Common Stock	$ 216,847